Celularity Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
115
- Stock Symbol
-
CELU
- Investments
-
7
- Share Price
-
$0.46
- (As of Friday Closing)
Celularity General Information
Description
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
Contact Information
Website
www.celularity.comCorporate Office
- 170 Park Avenue
- Florham Park, NJ 07039
- United States
Corporate Office
- 170 Park Avenue
- Florham Park, NJ 07039
- United States
Celularity Timeline
Celularity Stock Performance
As of 20-Nov-2026, Celularity’s stock price is $0.46. Its current market cap is $15M with 32.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.46 | $0.47 | $0.42 - $2.55 | $15M | 32.5M | 3.89M | -$1.69 |
Celularity Financials Summary
As of 30-Jun-2026, Celularity has a trailing 12-month revenue of $18.7M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 52,033 | 98,652 | 115,695 | 106,771 |
| Revenue | 18,666 | 26,550 | 54,220 | 22,771 |
| EBITDA | (36,386) | (77,926) | (44,037) | (184,266) |
| Net Income | (45,858) | (91,716) | (57,892) | (196,295) |
| Total Assets | 96,167 | 107,329 | 132,682 | 143,889 |
| Total Debt | 36,021 | 40,901 | 68,836 | 65,417 |
Celularity Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Celularity Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Celularity Comparisons
Industry
Financing
Details
Celularity Competitors (92)
One of Celularity’s 92 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA |
Celularity Patents
Celularity Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025160465-A1 | A method of treating signs or symptoms of the aging process | Pending | 26-Jan-2024 | ||
| WO-2025137471-A1 | Decellularized placenta extracellular matrix and uses thereof | Inactive | 20-Dec-2023 | ||
| WO-2025024825-A1 | Decellularized placental extracellular matrix and uses thereof | Inactive | 26-Jul-2023 | ||
| WO-2024197316-A1 | Bone growth composition | Inactive | 23-Mar-2023 | ||
| WO-2024167694-A2 | Placental extracellular matrices for ocular delivery of ophthalmic therapeutic agents | Inactive | 06-Feb-2023 | A61K9/0051 |
Celularity Signals
Celularity Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Celularity Investments & Acquisitions (7)
Celularity’s most recent deal was a Seed Round with DefEYE for . The deal was made on 31-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DefEYE | 31-Oct-2025 | Seed Round | Surgical Devices | ||
| Sequence LifeScience (Rebound Matrix) | 09-Oct-2024 | Corporate Asset Purchase | Buildings and Property | ||
| LifebankUSA | 23-Feb-2024 | Merger/Acquisition | Other Healthcare Services | ||
| GX Acquisition | 16-Jul-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Caricord | 31-Aug-2018 | Merger/Acquisition | Other Healthcare Services |
Celularity ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.89 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Celularity Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| LifebankUSA | Florham Park, NJ | 1996 |
Celularity FAQs
-
When was Celularity founded?
Celularity was founded in 1998.
-
Where is Celularity headquartered?
Celularity is headquartered in Florham Park, NJ.
-
What is the size of Celularity?
Celularity has 115 total employees.
-
What industry is Celularity in?
Celularity’s primary industry is Drug Discovery.
-
Is Celularity a private or public company?
Celularity is a Public company.
-
What is Celularity’s stock symbol?
The ticker symbol for Celularity is CELU.
-
What is the current stock price of Celularity?
As of 20-Nov-2026 the stock price of Celularity is $0.46.
-
What is the current market cap of Celularity?
The current market capitalization of Celularity is $15M.
-
What is Celularity’s current revenue?
The trailing twelve month revenue for Celularity is $18.7M.
-
Who are Celularity’s competitors?
Fate Therapeutics, Arvinas, uniQure, Mesoblast, and Sangamo Therapeutics are some of the 92 competitors of Celularity.
-
What is Celularity’s annual earnings per share (EPS)?
Celularity’s EPS for 12 months was -$1.69.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process